TrialHaematologica2016

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.

Guillaume Cartron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.